Science 37 alternatives for teams that need the technology without the services wrapper

Not in every case, and we'll tell you that honestly. Science 37's Metasite virtual site network, with mobile nurses, community clinics, and tele-visit infrastructure delivered as a managed service, is genuinely unique and valuable for trials that need physical presence at participants' homes or in local communities. If your protocol depends on a virtual site network, Science 37 (or their successor model post-eMed) is the right choice. WeGuide is the right choice when you need DCT architecture (eCOA, eConsent, telehealth, wearables, whitelabel app, engagement) as a configurable technology platform, and your in-person visits can be handled through your existing site network or a partner nursing service.

Yes. Decentralised trial architecture is a core WeGuide use case. Telehealth, eConsent, remote monitoring, eCOA, whitelabel participant apps, wearables, and engagement are all built in. The BRACE Trial is a good example of what a rapid-deploy decentralised trial looks like on our platform: 6,000+ participants across five countries in six weeks. The difference from Science 37 is that WeGuide runs the digital layer and leaves physical site operations to your existing network, rather than bundling a virtual site service alongside the software.

We coordinate with the sponsor's existing site network or with partner nursing services. WeGuide doesn't operate its own nurse network. For studies that need predictable mobile nurse coverage at scale, Science 37's Metasite model or a dedicated nursing partner is a better architectural fit than WeGuide on its own.

Science 37 typically combines the platform with virtual site services in project-based pricing, which means you're paying for both the technology and the services together. WeGuide is technology-only project pricing with every module included in the core licence. For studies that don't need the full Metasite services wrapper, WeGuide is typically lower-cost; for studies that do need the network, a direct pricing comparison is harder because you'd be comparing different scopes.

Science 37 was acquired by eMed in 2024. The combined entity's roadmap and product continuity have shifted, and some sponsors have reported uncertainty about where the Science 37 platform is heading under the new ownership structure. WeGuide's product roadmap is independently set by our product team alongside research delivery partners, and the platform has been in continuous development as WeGuide for seven years (with 15 years of combined digital health expertise behind it).

Possible, with planning. Mid study migrations typically need around six weeks for data export via the Integration Engine, regulatory documentation alignment, and participant re onboarding into the new whitelabel app. We'd walk through the specifics of your study on a discovery call before committing to a timeline; some protocols (especially those mid enrolment in a late stage Phase III) are genuinely harder to migrate than others.

For decentralised trials where the Metasite virtual site network is load-bearing, no. For decentralised trials where the digital layer (eCOA, eConsent, telehealth, wearables, engagement) is the critical component and in person touchpoints are handled through existing site networks, yes, and this is the most common shape of study we run.